DNA vaccine trial aims to wake up immune system against hepatitis b

NCT ID NCT00988767

Completed Disease control Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a DNA vaccine in 10 adults with chronic hepatitis B who had not responded to standard treatments. The vaccine was designed to train the immune system to fight the virus. The main goal was to check safety, with a secondary goal of seeing if the vaccine could restore immune responses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DNA vaccine (pCMV-S2.S DNA)
What this could lead to: If successful, this approach could help control chronic hepatitis B by boosting the immune system, potentially reducing the need for lifelong medication.
What could go wrong: This is a very early phase 1 trial with only 10 participants, so it is primarily testing safety. The vaccine may not produce strong enough immune responses to control the virus.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Locations

Service d'Hepatologie, Hopital Necker Enfants Malades

Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.